September 2021 - Incacare

Read more about the article A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation

A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation

Post author:admin
Post published:September 28, 2021
Post category:Journal Scan

Introduction Voriconazole is one of the first-line therapies for invasive pulmonary aspergillosis. Many factors, such as drug-drug interactions (DDIs), erratic absorption, and continuous renal replacement therapy (CRRT), influence voriconazole exposure,…

Read more about the article Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata

Post author:admin
Post published:September 13, 2021
Post category:Drug Updates

Introduction Candida glabrata is a new Candida species that causes infections ranging from minor to life-threatening systemic illness. Echinocandins and azoles are commonly employed as first-line therapy to treat C.…